by Admin Neo Lumina | Sep 28, 2023 | Press Release
NeoLumina Bioscience In-Licenses Clinical-stage Psilocybin Product Candidate from Filament Health for Eating Disorders PEX010 expands NeoLumina’s psychedelic product pipeline. Funding activity in process to advance clinical development. VANCOUVER, BRITISH COLUMBIA,...
by Admin Neo Lumina | Aug 28, 2023 | Press Release
NeoLumina Bioscience Advancing Development of Proprietary Psychedelic-based Therapeutic Medicines Funding activity initiated to advance lead psilocybin-based product candidate into human studies VANCOUVER, BC (August 30, 2023) – NeoLumina Bioscience Inc. (“NeoLumina”...
